(Q47303990)

13 January 2018

title

Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model (English)

1 reference

13 January 2018

1 reference

1

1 reference

13 January 2018

Xu-Feng Huang

series ordinal

4

1 reference

13 January 2018

Jiamei Lian

object named as

Jiamei Lian

series ordinal

2

0 references

author name string

Nagesh Pai

series ordinal

3

1 reference

13 January 2018

language of work or name

English

0 references

publication date

13 June 2012

1 reference

13 January 2018

Journal of Psychopharmacology

published in

1 reference

13 January 2018

volume

26

1 reference

13 January 2018

issue

9

1 reference

13 January 2018

page(s)

1271-1279

1 reference

13 January 2018

Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Pharmacokinetics and tissue distribution of olanzapine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Insulin resistance following continuous, chronic olanzapine treatment: an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

A parametric analysis of olanzapine-induced weight gain in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Antipsychotic drugs and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Second-generation antipsychotics for anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Binding affinity profile of betahistine and its metabolites for central histamine receptors of rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Characterization of olanzapine-induced weight gain in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Weight gain from novel antipsychotic drugs: need for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Betahistine: a retrospective synopsis of safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Dose translation from animal to human studies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Significant dissociation of brain and plasma kinetics with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112449396

21 January 2018

Identifiers

DOI

10.1177/0269881112449396

1 reference

13 January 2018

1 reference

13 January 2018